Showing 7121-7130 of 7634 results for "".
- FDA Warns on Acne Productshttps://practicaldermatology.com/news/20140627-fda_warns_on_acne_products/2459185/The FDA warns that using certain acne products containing benzoyl peroxide or salicylic acid can cause rare, but serious and in some cases life-threatening allergic reactions or severe irritation. Certain topical solutions cause: burning, dryness, itching, peeling, redness, and slight sw
- New National Psoriasis Foundation Program Prioritizes Psoriatic Arthritishttps://practicaldermatology.com/news/20140626-new_national_psoriasis_foundation_program_prioritizes_psoriatic_arthritis/2459186/According to the National Psoriasis Foundation (NPF), millions of Americans with psoriatic arthritis struggle to get the health care and treatments they need to manage their condition. To help change that, the NPF launched the largest realignment and expansion of its psoriatic a
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- FDA Issues Guidance Supporting the Responsible Development of Nanotechnology Productshttps://practicaldermatology.com/news/20140625-fda_issues_guidance_supporting_the_responsible_development_of_nanotechnology_products/2459190/Three final guidances and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products. Nanotechnology is an emerging technology allowing scientists to create, explore, and
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bact
- AMBI® Skincare Names Model Search Winnerhttps://practicaldermatology.com/news/20140623-ambi_skincare_names_model_search_winner/2459194/Charnee Long, 21, is the Grand Prize Winner of the first-ever nationwide AMBI® Model Search. Charnee was one of 10 finalists selected from a pool of more than 6,099 entrants. She will be featured in a national print campaign, receiving a three day/two night trip to New York City for a pro
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- AAD Issues Statement on Sunscreen Use and Melanoma Riskhttps://practicaldermatology.com/news/20140623-aad_issues_statement_on_sunscreen_use_and_melanoma_risk/2459197/American Academy of Dermatology (AAD) President Brett M. Coldiron, MD, FAAD issued a statement about sunscreen use and melanoma in response to a study that was recently published in the journal Nature.
- South Beach Symposium Debuts New Host Hotelhttps://practicaldermatology.com/news/20140623-south_beach_symposium_debuts_new_host_hotel/2459198/The 13th annual meeting of the South Beach Symposium moves to the Fontainebleau Hotel in Miami Beach, February 12-16, 2015. Faculty for the event have been announced on the SBS website. There are non-overlapping CME tracks: the Mas
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati